https://www.borgwarner.com/newsroom/press-releases/2021/12/15/borgwarner-enters-licensing-agreement-with-polycharge-america-inc.-for-disruptive-capacitor-technology
Exelixis And Iconic Therapeutics Amend Option And License Agreement For XB002; Exelixis Gains Full Rights To Use Anti-TF Antibody Incorporated Into XB002 For Any Application, Will Make One-Time Payment Of $55M
Exelixis, Inc. (NASDAQ:EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly
